Conferences

AIBCCR 2022: Cell-free DNA, Circulating Tumor Cells, Exosomes and Bladder Cancer September 18, 2022

AIBCCR 2022: The Implications of Biological Sex in Bladder Cancer September 17, 2022

AIBCCR 2022: T1 Bladder Cancer September 17, 2022

AIBCCR 2022: CAR-T Cells and Next Generation Immunotherapy for Bladder Cancer September 16, 2022

ESMO 2022: Invited Discussant: Results of COSMIC-313 September 13, 2022

ESMO 2022: Invited Discussant: Results of RADICALS-HD September 13, 2022

ESMO 2022: Observations on the Biology of PSMA Implications for Targeting September 13, 2022

ESMO 2022: Lu-PSMA for Prostate Cancer Treatment September 13, 2022

ESMO 2022: Latest Imaging Advances in PET and Beyond Translated to Bladder and Kidney Cancers September 13, 2022

ESMO 2022: PSMA Targeted T Cell Engagers September 13, 2022

ESMO 2022: Multidisciplinary Updates in Biomarkers in Urinary Cancers: The Microbiome September 13, 2022

ESMO 2022: Invited Discussant: The Phase III VESPER Trial & the Phase III CheckMate 274 Trial September 13, 2022

ESMO 2022: Pure or Mixed Basal/squamous Tumours Present Decreased Outcomes After Neoadjuvant Chemotherapy in the GETUG-AFU V05 VESPER Trial September 13, 2022

ESMO 2022: PSMA for Diagnosis and Staging September 13, 2022

ESMO 2022: Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma of Imdc Intermediate or Poor Risk (COSMIC-313) September 12, 2022

ESMO 2022: Duration of Androgen Deprivation Therapy with Post-Operative Radiotherapy for Prostate Cancer First Results of the RADICALS-HD Trial ISRCTN40814031 September 12, 2022

ESMO 2022: Invited Discussant: BIONIKK trial, Changes in Gut Microbiota, & LITESPARK-004 trial September 12, 2022

ESMO 2022: Invited Discussant: Results of the Phase 2 LITESPARK-003 Trial September 12, 2022

ESMO 2022: Longitudinal Analysis Reveals Gut Microbiota Shift During Standard Therapies in Metastatic Renal Cell Carcinoma (mRCC) September 12, 2022

ESMO 2022: Invited Discussant: The Results of the PIVOT-09 Trial & the Role of Enfortumab Vedotin September 12, 2022

Page 1 of 480

email news signup